# Grace Therapeutics, Inc.: overview GRCE · Nasdaq · CIK 1444192 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/grce.md) · [Financials](/companies/grce/financials.md) · [Filings](/companies/grce/filings.md) · [Insiders](/companies/grce/insiders.md) Latest reported revenue: [$100.0m](/filings/0000950170-23-029498.md) for Q4 FY2022, three months to 2022-03-31, from the 10-K filed Jun 23, 2023 (XBRL us-gaap:Revenues, accession 0000950170-23-029498). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.30)](/filings/0001140361-25-041804.md) | [(0.36)](/filings/0001140361-26-004924.md) | not reported | [(0.21)](/filings/0001140361-26-032632.md) | [(0.06)](/filings/0001140361-25-041804.md) | [(0.14)](/filings/0001140361-26-004924.md) | not reported | [(0.91)](/filings/0001140361-26-032632.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [100](/filings/0000950170-23-029498.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(15.6%)](/filings/0000950170-23-029498.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(9.8%)](/filings/0000950170-23-029498.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0000950170-23-029498.md) | [(5.71)](/filings/0000950170-24-075875.md) | [(1.35)](/filings/0001140361-25-023259.md) | [(0.79)](/filings/0001140361-26-025662.md) | [(0.47)](/filings/0001140361-26-025662.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/grce/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-26 | [Opaleye Management Inc.](/insiders/1595855.md) | 10% owner | Purchase (P) | 66,411 | $1.7679 | $117.4k | [Form 4](/filings/0001493152-26-048591.md) | | 2026-10-22 | [Opaleye Management Inc.](/insiders/1595855.md) | 10% owner | Purchase (P) | 21,390 | $1.9258 | $41.2k | [Form 4](/filings/0001493152-26-048591.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cerity Partners LLC](/funds/1566475.md) | 2026-06-30 | $1.9m | 849,055 | | Unchanged | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $1.8m | 772,900 | | Added +16,300 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $1.1m | 494,698 | | Reduced −25 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $934.6k | 411,714 | | Added +10,058 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $793.9k | 349,740 | | Added +250,998 | | [Maven Securities LTD](/funds/1633046.md) | 2026-06-30 | $454.0k | 200,000 | | New +200,000 | | [Birchview Capital, LP](/funds/1618205.md) | 2026-06-30 | $272.4k | 120,000 | | Added +70,000 | | [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $227.0k | 100,000 | | New +100,000 | | [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $227.0k | 100,000 | | New +100,000 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $219.9k | 96,890 | | New +96,890 | ## Recent filings [All 589 filings](/companies/grce/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-18 | 16:06 ET | [8-K](/filings/0001140361-26-037114.md) | 5.07 Shareholder vote results | 0001140361-26-037114 | | 2026-08-13 | 08:01 ET | [8-K](/filings/0001140361-26-032644.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032644 | | 2026-08-13 | 07:30 ET | [10-Q](/filings/0001140361-26-032632.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032632 | | 2026-08-06 | 16:06 ET | [8-K](/filings/0001140361-26-031671.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-031671 | | 2026-07-28 | 16:29 ET | [DEF 14A](/filings/0001140361-26-029889.md) | Proxy statement, period 2026-09-17 | 0001140361-26-029889 | | 2026-07-28 | 07:16 ET | [8-K](/filings/0001140361-26-029837.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-029837 | | 2026-06-18 | 08:15 ET | [8-K](/filings/0001140361-26-025669.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-025669 | | 2026-06-18 | 08:01 ET | [8-K](/filings/0001140361-26-025667.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-025667 | | 2026-06-18 | 07:31 ET | [10-K](/filings/0001140361-26-025662.md) | Annual report, period 2026-03-31 | 0001140361-26-025662 | | 2026-06-05 | 16:09 ET | [8-K](/filings/0001140361-26-024269.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-024269 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001140361-26-025662.md), filed Jun 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1444192 - Tickers: GRCE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 18:07 ET. No prices; not investment advice.